Cover Image

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence

Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. However, randomised controlled trials may not fully capture the diversity of real-world patients. This study aims to evaluate im...

Full description

Saved in:
Bibliographic Details
Main Authors: Surovtsova, Irina (Author) , Herth, Felix (Author) , Kokh, Daria B. (Author) , Morakis, Philipp (Author)
Format: Article (Journal)
Language:English
Published: 05 Feb 2025
In: Pulmonology
Year: 2025, Volume: 31, Issue: 1, Pages: 1-11
ISSN:2531-0437
DOI:10.1080/25310429.2025.2457856
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1080/25310429.2025.2457856
Get full text
Author Notes:Irina Surovtsova, Felix J.F. Herth, Daria B. Kokh and Philipp Morakis
Description
Summary:Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. However, randomised controlled trials may not fully capture the diversity of real-world patients. This study aims to evaluate immunochemotherapy outcomes in a real-world setting, including subgroups underrepresented in the KEYNOTE-189 trial. Patients diagnosed with non-squamous mNSCLC 2011-2022 and recorded in Cancer Registry Database of the German Federal State Baden-Württemberg (BWCR), were analysed. OS was assessed using Kaplan-Meier and multivariable Cox models, adjusted for major clinical parameters. Results were compared with KEYNOTE-189. Among 2630 eligible cases, 1314 patients received chemotherapy alone and 1316 received immunochemotherapy. Median OS (mOS) was 14.1 months (95%CI: 13.1-15.4) for immunochemotherapy and 10.4 months (95%CI: 9.7-11.2) for chemotherapy alone, with an HR of 0.7 (95%CI: 0.64-0.77). A significant benefit was seen in M1c stage (HR 0.7, 95%CI: 0.63-0.79). No significant OS improvement was observed in patients with ECOG 2-3 or bone metastases. This real-world evidence suggests that immunochemotherapy generally improves OS in mNSCLC. Subgroup analysis showed no survival benefit for patients with ECOG >1 or bone metastasis, but a benefit for patients with M1c stage.
Item Description:Gesehen am 24.07.2025
Physical Description:Online Resource
ISSN:2531-0437
DOI:10.1080/25310429.2025.2457856

Similar Items